Striatal cell-type-specific molecular signatures reveal therapeutic targets in a model of dystonia

Kaitlyn M Roman,Ashok R Dinasarapu,Suraj Cherian,Xueliang Fan,Yuping Donsante,Nivetha Aravind,C Savio Chan,H A Jinnah,Ellen J Hess

DOI: https://doi.org/10.1101/2024.10.07.617010

2024-10-07

Abstract:Striatal dysfunction is implicated in many forms of dystonia, including idiopathic, inherited and iatrogenic dystonias. The striatum is comprised largely of GABAergic spiny projection neurons (SPNs) that are defined by their long-range efferents. Direct SPNs (dSPNs) project to the internal globus pallidus/substantia nigra reticulata whereas indirect pathway SPNs (iSPNs) project to the external pallidum; the concerted activity of both SPN subtypes modulates movement. Convergent results from genetic, imaging and physiological studies in patients suggest that abnormalities of both dSPNs and iSPNs contribute to the expression of dystonia, but the molecular adaptations underlying these abnormalities are not known. Here we provide a comprehensive analysis of SPN cell-type specific molecular signatures in a model of DOPA-responsive dystonia (DRD mice), which is caused by gene defects that reduce dopamine neurotransmission, resulting in dystonia that is specifically associated with striatal dysfunction. Individually profiling the translatome of dSPNs and iSPNs using translating ribosome affinity purification with RNA-seq revealed hundreds of differentially translating mRNAs in each SPN subtype in DRD mice, yet there was little overlap between the dysregulated genes in dSPNs and iSPNs. Despite the paucity of shared adaptations, a disruption in glutamatergic signaling was predicted for both dSPNs and iSPNs. Indeed, we found that both AMPA and NMDA receptor-mediated currents were enhanced in dSPNs but diminished in iSPNs in DRD mice. The pattern of mRNA dysregulation was specific to dystonia as the adaptations in DRD mice were distinct from those in parkinsonian mice where the dopamine deficit occurs in adults, suggesting that the phenotypic outcome is dependent on both the timing of the dopaminergic deficit and the SPN-specific adaptions. We leveraged the unique molecular signatures of dSPNs and iSPNs in DRD mice to identify biochemical mechanisms that may be targets for therapeutics, including LRRK2 inhibition. Administration of the LRRK2 inhibitor MLi-2 ameliorated the dystonia in DRD mice suggesting a novel target for therapeutics and demonstrating that the delineation of cell-type specific molecular signatures provides a powerful approach to revealing both CNS dysfunction and therapeutic targets in dystonia.

Neuroscience

What problem does this paper attempt to address?

This paper aims to solve the problem of the specific molecular mechanisms of basal ganglia dysfunction in DOPA - responsive dystonia (DRD). DRD is a movement disorder caused by a reduction in dopamine neurotransmission due to genetic defects, mainly manifested as involuntary muscle contractions, resulting in distorted movements and postures. Although DRD can be treated by supplementing L - DOPA, the specific abnormal functions of nerve cells and their molecular adaptation mechanisms are not yet fully understood.

Specifically, by analyzing the transcriptome characteristics of direct pathway spiny projection neurons (dSPNs) and indirect pathway spiny projection neurons (iSPNs) in the DRD mouse model, researchers attempt to reveal the specific molecular changes of these neurons in DRD. These changes may include differences in gene expression, alterations in signaling pathways, etc., thus providing a new perspective for understanding the pathological mechanism of DRD and potential targets for the development of treatment methods for DRD.

The key findings of the study include:
- dSPNs and iSPNs show specific molecular adaptations in DRD mice, and there is almost no overlap between them.
- Despite different molecular adaptations, disruption of glutamatergic signaling is predicted in both types of SPNs.
- Experimental results show that AMPA - and NMDA - receptor - mediated currents are enhanced in dSPNs and weakened in iSPNs.
- These patterns of molecular adaptations are different in DRD mice from those in Parkinson's disease mice, indicating that phenotypic outcomes depend on the duration of dopamine deficiency and SPN - specific adaptation.

In addition, by using the LRRK2 inhibitor MLi - 2 to treat DRD mice, the study found that this drug can improve the dystonia symptoms of DRD mice, suggesting that LRRK2 may be a new target for the treatment of DRD. These findings not only enhance the understanding of the pathological mechanism of DRD but also provide a scientific basis for the development of new treatment strategies.